TFF Pharmaceuticals Inc. closed a $1.2 million registered direct offering priced at-the-market under Nasdaq rules.

Mar 26, 2024•over 1 year ago

Amount Raised

$1.2 Million

Round Type

seed

Fort Worth

Investors

H.C. Wainwright & Co.

Description

TFF Pharmaceuticals, Inc announced the closing of a registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 147,500 shares of common stock at a purchase price of $8.00 per share. The gross proceeds to the company from the offering were approximately $1.2 million, with the net proceeds intended for working capital and general corporate purposes.

Company Information

Company

TFF Pharmaceuticals, Inc.

Location

2600 VIA FORTUNA

Fort Worth, Texas, United States

About

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: TFF VORI (Voriconazole Inhalation Powder) and TFF TAC (Tacrolimus Inhalation Powder). The Company continues collaborations with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.

Related People

9 contacts

Funding Insights

Based on industry data

VC-backed spending patterns